DGX vs HUM: fair value comparison
Quest Diagnostics Incorporated and Humana Inc. · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, DGX currently sits closer to the top of our discount ranking.
| DGX | HUM | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $242.76 | $385.54 |
| 12-month range | $173.79–$233.01 | $176.95–$374.50 |
| Sector rank | #105 of 113 Healthcare | #108 of 113 Healthcare |
| Quality grade | C | C |
| Momentum grade | B | — |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Fairly Valued | Fairly Valued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: DGX fair value analysis · HUM fair value analysis